IE36269B1 - Substituted pyrido (3,2-d) pyrimidines - Google Patents

Substituted pyrido (3,2-d) pyrimidines

Info

Publication number
IE36269B1
IE36269B1 IE461/72A IE46172A IE36269B1 IE 36269 B1 IE36269 B1 IE 36269B1 IE 461/72 A IE461/72 A IE 461/72A IE 46172 A IE46172 A IE 46172A IE 36269 B1 IE36269 B1 IE 36269B1
Authority
IE
Ireland
Prior art keywords
group
compounds
chloro
amino
thiol
Prior art date
Application number
IE461/72A
Other versions
IE36269L (en
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712117657 external-priority patent/DE2117657B2/en
Priority claimed from DE19722202367 external-priority patent/DE2202367A1/en
Priority claimed from DE19722208534 external-priority patent/DE2208534A1/en
Priority claimed from DE19722208535 external-priority patent/DE2208535A1/en
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of IE36269L publication Critical patent/IE36269L/en
Publication of IE36269B1 publication Critical patent/IE36269B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

1382487 Substituted pyrido-pyrimidine compounds DR KARL THOMAE GmbH 7 April 1972 [10 April 1971 19 Jan 1972 23 Feb 1972 (2)] 16212/72 Heading C2C Novel compounds of the Formula I wherein R 1 and R 2 , which are the same or different, each are morpholino, thiomorpholino, 1-oxidothiomorpholino, 1,1 -dioxidothiomorpholino or piperidino each of which is optionally substituted by C 1-3 alkyl; piperazino optionally substituted in the 4-position by acyl, carbethoxy, carbamoyl or C 1-3 alkyl; or a dialkanolamino or aminoalkylamino; and R 3 is hydrogen or methyl and said addition salts thereof may be prepared by (a) reacting a compound II wherein one or both of Z 1 and Z 2 are groups replaceable by amino and the other Z group if not replaceable by amino is R 1 or R 2 as above, with an amine R 1 -H or R 2 H; (b) removing or introducing an acyl or carbethoxy group from or into a piperazine ring; (c) oxidizing a thiomorpholine group to 1-oxido or 1,1-dioxido-thiomorpholine; (d) reacting a compound VI with crotonaldehyde, acrolein or glycerine in the presence of an oxidizing agent and an acidic condensation agent. The intermediates VI may be formed from 2,4-dichloro-5-nitro-pyrimidine by introducing the R 1 and R 2 by a process corresponding to (a) followed by reduction of the nitro group to amino. The intermediates II may be formed by converting (a) keto to chloro, (b) chloro to thiol, (c) thiol to alkylsulphonyl, or (d) chloro to phenoxy followed where applicable by introduction of one of the groups R 1 and R 2 . Pharmaceutical compositions of the compounds I inhibit aggregation of thrombocytes in human blood when administered orally, rectally or parenterally. Certain compounds I also have blood pressure lowering properties. [GB1382487A]
IE461/72A 1971-04-10 1972-04-10 Substituted pyrido (3,2-d) pyrimidines IE36269B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19712117657 DE2117657B2 (en) 1971-04-10 1971-04-10 PYRIDO SQUARE BRACKET ON 3.2-ANGLE BRACKET FOR PYRIMIDINE
DE19722202367 DE2202367A1 (en) 1972-01-19 1972-01-19 Pyrido(3,2-d)pyrimidines - anticoagulants
DE19722208534 DE2208534A1 (en) 1972-02-23 1972-02-23 Pyrido(3,2-d)pyrimidines - anticoagulants
DE19722208535 DE2208535A1 (en) 1972-02-23 1972-02-23 Pyrido(3,2-d)pyrimidines - anticoagulants

Publications (2)

Publication Number Publication Date
IE36269L IE36269L (en) 1972-10-10
IE36269B1 true IE36269B1 (en) 1976-09-29

Family

ID=27431239

Family Applications (1)

Application Number Title Priority Date Filing Date
IE461/72A IE36269B1 (en) 1971-04-10 1972-04-10 Substituted pyrido (3,2-d) pyrimidines

Country Status (8)

Country Link
BE (1) BE781900A (en)
CA (1) CA992081A (en)
DD (1) DD97204A5 (en)
GB (1) GB1382487A (en)
HU (1) HU164346B (en)
IE (1) IE36269B1 (en)
IL (1) IL39174A (en)
NL (1) NL7204783A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912336D0 (en) * 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds

Also Published As

Publication number Publication date
HU164346B (en) 1974-01-28
GB1382487A (en) 1975-02-05
CA992081A (en) 1976-06-29
IL39174A0 (en) 1972-06-28
NL7204783A (en) 1972-10-12
IE36269L (en) 1972-10-10
IL39174A (en) 1975-02-10
BE781900A (en) 1972-10-10
DD97204A5 (en) 1973-04-20

Similar Documents

Publication Publication Date Title
GB1449100A (en) Pyrimidine derivatives processes for their preparation and their use in pharmaceutical compositions
GB1376096A (en) 1-3,4-methylenedioxy-phenyl-4,4-dimethyl-1-pentene derivatives
GB1435573A (en) Indoloquinolizines
IE42979L (en) Pyrazinyl piperazine derivatives
IE36269B1 (en) Substituted pyrido (3,2-d) pyrimidines
GB1432660A (en) Piperazine derivatives processes for their preparation and and pharamacueitcal compositions containing them
GB1225462A (en)
GB1390658A (en) Thiazolopyrimidine derivatives
GB1399470A (en) Derivatives of pyrazolopyridine ketones
GB1369294A (en) Purine-ribofuranoside-2,5,-cyclophosphates
GB1361863A (en) Piperazine derivatives their preparation and pharmaceutical compositions containing them
IE38101B1 (en) 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines
GB1426685A (en) 1,3-bis -beta-ethylhexyl-5 amino-5-methylhexahydropyrimidine- pyridine-3-carboxylate
EP0076452A3 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE3580888D1 (en) 2-AMINOTHIAZOLE DERIVATIVES HAVING AN ACID ELIMINATING EFFECT.
GB1374326A (en) Amino acids
GB1172554A (en) Bis-Thiosemicarbazones and a process for their manufacture
GB1425049A (en) Substituted 2-hydroxy-2-phenylethyl-amines
GB1361779A (en) Vincamine salt and its use as a pharmaceutical composition
IE33870B1 (en) Benzobenzofuranooxepine compounds and process for preparing the same
IE820684L (en) Hydroxamic acid derivatives.
GB1207116A (en) Morphanthridine derivatives
GB1474040A (en) Chlorosulphonyl-benzaldehydr derivatives
GB1214264A (en) 2-substituted derivatives of 6-methoxyquinoline
GB1263677A (en) Process for the preparation of quinoxaline-di-n-oxide-aldehyde